Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

OBJECTIVE: Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (TC). METHODS: We pooled...

Descripción completa

Detalles Bibliográficos
Autores principales: Waguespack, Steven G, Drilon, Alexander, Lin, Jessica J, Brose, Marcia S, McDermott, Ray, Almubarak, Mohammed, Bauman, Jessica, Casanova, Michela, Krishnamurthy, Anuradha, Kummar, Shivaani, Leyvraz, Serge, Oh, Do-Youn, Park, Keunchil, Sohal, Davendra, Sherman, Eric, Norenberg, Ricarda, Silvertown, Josh D, Brega, Nicoletta, Hong, David S, Cabanillas, Maria E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066591/
https://www.ncbi.nlm.nih.gov/pubmed/35333737
http://dx.doi.org/10.1530/EJE-21-1259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066591/
https://www.ncbi.nlm.nih.gov/pubmed/35333737
http://dx.doi.org/10.1530/EJE-21-1259

Ejemplares similares